Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

Gideon M. Hirschfield, Olivier Chazouillères, Joost P. Drenth, Douglas Thorburn, Stephen A. Harrison, Charles S. Landis, Marlyn J Mayo, Andrew J. Muir, James F. Trotter, Diana J. Leeming, Morten A. Karsdal, Mark J. Jaros, Lei Ling, Kathline H. Kim, Stephen J. Rossi, Ransi M. Somaratne, Alex M. DePaoli, Ulrich Beuers

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences